Goldman Sachs
EIDX

Goldman Sachs’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Goldman Sachs’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-147,421
Closed -$19.4M – 6576
2020
Q4 		$19.4M Buy
147,421
+123,062
+505% +$10.9M 0.01% 1884
2020
Q3 		$1.23M Sell
24,359
-7,741
-24% -$348K ﹤0.01% 3934
2020
Q2 		$1.53M Sell
32,100
-2,767
-8% -$129K ﹤0.01% 3643
2020
Q1 		$1.71M Sell
34,867
-16,131
-32% -$822K ﹤0.01% 3407
2019
Q4 		$2.93M Buy
50,998
+14,404
+39% +$713K ﹤0.01% 3376
2019
Q3 		$1.32M Buy
36,594
+17,929
+96% +$700K ﹤0.01% 3847
2019
Q2 		$580K Sell
18,665
-1,063
-5% -$28.8K ﹤0.01% 4317
2019
Q1 		$463K Sell
19,728
-8,062
-29% -$129K ﹤0.01% 4453
2018
Q4 		$382K Buy
27,790
+12,839
+86% +$162K ﹤0.01% 4519
2018
Q3 		$149K Sell
14,951
-16,741
-53% -$275K ﹤0.01% 5007
2018
Q2 		$645K Buy
+31,692
New +$664K ﹤0.01% 4359

Goldman Sachs's EIDX Position: Q1 2021 in Review

Goldman Sachs sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 147,421 shares — an estimated $19.4M sold.

Goldman Sachs first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $19.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Goldman Sachs reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Goldman Sachs sold 147,421 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $19.4M.
  • Goldman Sachs first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Goldman Sachs's Eidos Therapeutics, Inc. Common Stock position peaked at $19.4M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.